AR008621A1 - A COMPOUND DERIVED FROM SUCCINIC AMINE, A PROCEDURE FOR CARRYING OUT ITS PREPARATION AND A PHARMACEUTICAL COMPOSITION INCLUDING SUCH A COMPOSITION - Google Patents

A COMPOUND DERIVED FROM SUCCINIC AMINE, A PROCEDURE FOR CARRYING OUT ITS PREPARATION AND A PHARMACEUTICAL COMPOSITION INCLUDING SUCH A COMPOSITION

Info

Publication number
AR008621A1
AR008621A1 ARP970102813A ARP970102813A AR008621A1 AR 008621 A1 AR008621 A1 AR 008621A1 AR P970102813 A ARP970102813 A AR P970102813A AR P970102813 A ARP970102813 A AR P970102813A AR 008621 A1 AR008621 A1 AR 008621A1
Authority
AR
Argentina
Prior art keywords
procedure
preparation
carrying
compound derived
pharmaceutical composition
Prior art date
Application number
ARP970102813A
Other languages
Spanish (es)
Original Assignee
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa
Publication of AR008621A1 publication Critical patent/AR008621A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Los derivados de amida succínica de la formula (I) en donde W es un grupo -CO2H o -CONHOH; R, R1 y R2 SON, cada una de ellas, hidrogeno o un residuoorgánico, R3 es el residuo de un alfa-aminoácido y R4 es un grupo orgánico, constituyen los inhibidores de metaloproteinasas de matriz (MMPs) y de laliberacion de los factores-alfa de necrosis tumoral (TNF) de las células y que resultan, en consecuencia, utiles para la prevencion, el control y eltratamiento de las enfermedades en las cuales seencuentran involucrados los MMPs o TNF. También se describe un procedimiento para llevar a cabo supreparacion y las composiciones farmacéuticas que los contienen.The succinic amide derivatives of formula (I) wherein W is a group -CO2H or -CONHOH; R, R1 and R2 ARE, each of them, hydrogen or an organic residue, R3 is the residue of an alpha-amino acid and R4 is an organic group, they constitute the inhibitors of matrix metalloproteinases (MMPs) and of the release of the factors- tumor necrosis alpha (TNF) of cells and, consequently, are useful for the prevention, control and treatment of diseases in which MMPs or TNF are involved. A procedure for carrying out the preparation and the pharmaceutical compositions containing them are also described.

ARP970102813A 1996-06-27 1997-06-26 A COMPOUND DERIVED FROM SUCCINIC AMINE, A PROCEDURE FOR CARRYING OUT ITS PREPARATION AND A PHARMACEUTICAL COMPOSITION INCLUDING SUCH A COMPOSITION AR008621A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9613547.0A GB9613547D0 (en) 1996-06-27 1996-06-27 Matrix metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
AR008621A1 true AR008621A1 (en) 2000-02-09

Family

ID=10796022

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970102813A AR008621A1 (en) 1996-06-27 1997-06-26 A COMPOUND DERIVED FROM SUCCINIC AMINE, A PROCEDURE FOR CARRYING OUT ITS PREPARATION AND A PHARMACEUTICAL COMPOSITION INCLUDING SUCH A COMPOSITION

Country Status (18)

Country Link
EP (1) EP0920414A1 (en)
JP (1) JP2000514043A (en)
KR (1) KR20000022534A (en)
AR (1) AR008621A1 (en)
AU (1) AU733938B2 (en)
BR (1) BR9709902A (en)
CA (1) CA2257404A1 (en)
CZ (1) CZ430398A3 (en)
EA (1) EA001432B1 (en)
GB (1) GB9613547D0 (en)
ID (1) ID17792A (en)
IL (1) IL127262A0 (en)
NO (1) NO986049L (en)
NZ (1) NZ333550A (en)
PL (1) PL330897A1 (en)
TW (1) TW460441B (en)
WO (1) WO1997049674A1 (en)
ZA (1) ZA975631B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19719817A1 (en) * 1997-05-13 1998-11-19 Hoechst Ag Substituted 6- and 7-aminotetrahydroisoquinoline carboxylic acids
IL134273A0 (en) * 1997-07-31 2001-04-30 Procter & Gamble Acyclic metalloprotease inhibitors
GB9803005D0 (en) 1998-02-12 1998-04-08 British Biotech Pharm Anti-inflammatory agents
GB9804777D0 (en) * 1998-03-07 1998-04-29 British Biotech Pharm Anti-inflammatory agents
US6335324B1 (en) 1998-06-25 2002-01-01 Bristol-Myers Squibb Co. Beta lactam compounds and their use as inhibitors of tryptase
GB9901863D0 (en) * 1999-01-29 1999-03-17 British Biotech Pharm Antibacterial agents
WO2000051975A1 (en) 1999-03-03 2000-09-08 The Procter & Gamble Company Alkenyl- and alkynyl-containing metalloprotease inhibitors
CA2393825A1 (en) * 1999-12-17 2001-06-21 Versicor, Inc. Novel succinate compounds, compositions and methods of use and preparation
GB9930754D0 (en) * 1999-12-29 2000-02-16 Smithkline Beecham Plc Novel compounds
AU2001271068A1 (en) * 2000-07-18 2002-01-30 Chugai Seiyaku Kabushiki Kaisha Matrix metalloprotease inhibitors
WO2002102791A1 (en) 2001-06-15 2002-12-27 Vicuron Pharmaceuticals Inc. Pyrrolidine bicyclic compounds
AR036053A1 (en) 2001-06-15 2004-08-04 Versicor Inc N-FORMIL-HYDROXYLAMINE COMPOUNDS, A PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS
US20110230479A1 (en) * 2005-04-15 2011-09-22 Longo Frank M Neurotrophin mimetics and uses thereof
KR20060116552A (en) * 2005-05-10 2006-11-15 연세대학교 산학협력단 N-formyl hydroxylamine derivatives as matrix metalloproteinase inhibitors
FR2949463B1 (en) * 2009-08-26 2011-09-16 Commissariat Energie Atomique MMP INHIBITORS
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
EP2498782B1 (en) 2009-11-12 2019-01-09 Pharmatrophix Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
US20210393632A1 (en) 2018-10-04 2021-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
DK77487A (en) * 1986-03-11 1987-09-12 Hoffmann La Roche hydroxylamine
EP0489579B1 (en) * 1990-12-03 1995-03-29 Celltech Therapeutics Limited Peptidyl derivatives
CA2058797A1 (en) * 1991-02-01 1992-08-02 Michael John Broadhurst Amino acid derivatives
EP0520573A1 (en) * 1991-06-27 1992-12-30 Glaxo Inc. Cyclic imide derivatives

Also Published As

Publication number Publication date
NO986049D0 (en) 1998-12-22
CZ430398A3 (en) 1999-08-11
AU733938B2 (en) 2001-05-31
EA199900057A1 (en) 1999-06-24
ZA975631B (en) 1998-01-30
EA001432B1 (en) 2001-02-26
EP0920414A1 (en) 1999-06-09
TW460441B (en) 2001-10-21
WO1997049674A1 (en) 1997-12-31
BR9709902A (en) 1999-08-10
IL127262A0 (en) 1999-09-22
CA2257404A1 (en) 1997-12-31
JP2000514043A (en) 2000-10-24
AU3342297A (en) 1998-01-14
NZ333550A (en) 2000-07-28
PL330897A1 (en) 1999-06-07
KR20000022534A (en) 2000-04-25
GB9613547D0 (en) 1996-08-28
ID17792A (en) 1998-01-29
NO986049L (en) 1999-03-01

Similar Documents

Publication Publication Date Title
AR008621A1 (en) A COMPOUND DERIVED FROM SUCCINIC AMINE, A PROCEDURE FOR CARRYING OUT ITS PREPARATION AND A PHARMACEUTICAL COMPOSITION INCLUDING SUCH A COMPOSITION
ES2137998T3 (en) NEW AMINO ACID DERIVATIVES, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINED IN THESE COMPOUNDS.
BR9815398A (en) Compound, pharmaceutical composition, method for treating or preventing an inflammatory disorder, method of treating an mmps-mediated condition or disease and method of treating a condition or disease
PE20030894A1 (en) ACRIDONE AS INHIBITORS OF THE IMPDH ENZYME
AR034268A1 (en) COMPOUNDS DERIVED FROM PIPERIDINE, ITS USE IN PREPARATION OF MEDICINES, PHARMACEUTICAL COMPOSITION, TREATMENT METHOD AND PROCESS FOR PREPARATION
BR9713465A (en) Cytically substituted amine metallotprotease inhibitors
BR0312999A (en) Compounds, pharmaceutical compositions, method for enhancing cognition, treatment, inhibiting pde4 enzyme activity in a patient
AR029216A1 (en) NON-PEPTIDIC INHIBITING COMPOUNDS OF THE VLA-4 DEPENDENT CELL UNION IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE AND RESPIRATORY DISEASES; PHARMACEUTICAL COMPOSITION AND TREATMENT PROCEDURE
AR012264A1 (en) COMPOUND, PHARMACEUTICAL COMPOSITION AND METHOD TO OBTAIN THE COMPOSITION TO PREVENT OR AVOID A DISEASE ASSOCIATED WITH UNDESIATED METALOPROTEASICAL ACTIVITY
DE60132309D1 (en) AMIN DERIVATIVES FOR THE TREATMENT OF APOPTOSIS
DK0889877T3 (en) Meta-substituted phenylene derivatives and their use as alpha-beta3 integrin antagonists or inhibitors
AR030959A1 (en) DERIVATIVES OF AMINOALCOHOLES, PROCEDURE TO PREPARE THEM, THE USE OF THE SAME TO PREPARE DRUGS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR016762A1 (en) 4-BROMO OR 4-IODINE PHENYLAMINE BENZOHIDROXAMIC ACID COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USE OF THE SAME
AR016429A1 (en) COMPOUND DERIVED FROM HYDROXAMIC ACID AS MATRIX METALOPROTEASE (MMP) INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND VETERINARY FORMULATIONS, USOPARES THE PREPARATION OF COMPOSITIONS AND FORMULATIONS, INTERMEDIARY COMPOUND, PROCEDURE FOR PREPARATION OF COMPOSITION.
CO5550421A2 (en) INDOL DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASE
PE20090620A1 (en) DERIVATIVES OF 1,2,4,5-TETRAHIDRO-3H-BENZAZEPINEAS, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ATE280763T1 (en) MATRIX METALLOPROTEINASE INHIBITORS
AR004961A1 (en) (R) - (-) - 2- {N- [4- (1,1-DIOXIDO-3- OXO-2,3-DIHIDRO-BENZISOTIAZOLE-2-IL) -BUTYL] -AMINOMETIL CRYSTALLINE V MODIFICATION ) CHROMAN, A PROCEDURE FOR ITS PREPARATION, MEDICINES CONTAINING IT, THE USE OF SUCH CHLORHYDRATE FOR THE PREPARATION OF MEDICINES, A COMPOSITION FOR
NO20025641D0 (en) Substituted 1-aminoalkyl lactams and their use as muscarinic receptor antagonists
AR018139A1 (en) A N- [3-HIDROXI-5 [(1,4,5,6-TETRAHIDRO-5-HIDROXI-2-PYRIMIDINYL) AMINO] BENZOIL] GLICI-3- (3-HALO-5-HALO-2-HYDROXYPHENYL) COMPOUND ) -BALL ALANINE, COMPOSITION PHARMACEUTICAL AND USE OF THE SAME IN THE MANUFACTURE OF A MEDICINAL PRODUCT.
CR10974A (en) CARBOXIPEPTIDASE B PLASMATIC INHIBITORS (DIVISIONAL)
ES2113664T3 (en) AMINO ACID DERIVATIVES AS NO SINTASA INHIBITORS.
ES2038172T3 (en) PROCEDURE FOR PREPARING HETERO CYCLIC CARBOXAMIDES.
AR007079A1 (en) DERIVATIVES OF ALKYLAMOBENZOTIAZOLE AND BENZOXAZOLE, A PROCESS FOR THEIR PREPARATION, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM, AND A PROCESS TO PREPARE SUCH COMPOSITION
CL2003002565A1 (en) COMPOUNDS DERIVED FROM 3H-QUINAZOLIN-4-ONA, ITS PREPARATION PROCESS, PHARMACEUTICAL COMPOSITION CONTAINING THEM, AND USE IN THE TREATMENT AND PREVENTION OF DISEASES MEDIATED BY MAO-B INHIBITORS, SUCH AS THE DISEASE OF ALZHEIMER AND DEMENCIER